M A Morse

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Dendritic cell-based approaches to cancer immunotherapy
    M A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    Expert Opin Investig Drugs 7:1617-27. 1998
  2. ncbi request reprint American Society of Clinical Oncology - 36th Annual Meeting
    M A Morse
    Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    IDrugs 3:846-50. 2000
  3. ncbi request reprint Stem cell therapy (Aastrom Biosciences Inc)
    M A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    IDrugs 3:346-53. 2000
  4. pmc Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
    Xiu Rong Ren
    Department of Medicine, Duke University Medical Center, 595 LaSalle Street, Durham, NC 27710, USA
    Breast Cancer Res 14:R89. 2012
  5. pmc Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines
    Fatima Rangwala
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BMC Cancer 12:402. 2012
  6. pmc Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Immunol Immunother 62:1293-301. 2013
  7. doi request reprint Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma
    Michael A Morse
    Duke University Medical Center, Durham, NC, USA
    Clin Colorectal Cancer 11:185-90. 2012
  8. pmc Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
  9. pmc Investigation of HIFU-induced anti-tumor immunity in a murine tumor model
    Zhenlin Hu
    Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
    J Transl Med 5:34. 2007
  10. pmc Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
    Holden T Maecker
    BD Biosciences, San Jose, CA, USA
    BMC Immunol 9:9. 2008

Research Grants

  1. DEXASOME BASED IMMUNOTHERAPY OF LUNG CANCER
    Michael Morse; Fiscal Year: 2002
  2. Vaccination with Regulatory T Cell Depletion
    Michael Morse; Fiscal Year: 2007

Detail Information

Publications117 found, 100 shown here

  1. ncbi request reprint Dendritic cell-based approaches to cancer immunotherapy
    M A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    Expert Opin Investig Drugs 7:1617-27. 1998
    ..Although the commercial applicability of dendritic cell-based immunotherapy has been recognised by the biotechnology industry, commercial availability of dendritic cell vaccines await phase III studies...
  2. ncbi request reprint American Society of Clinical Oncology - 36th Annual Meeting
    M A Morse
    Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    IDrugs 3:846-50. 2000
    ..While there were no agents with unexpectedly dramatic clinical benefit, there were a number of promising developments...
  3. ncbi request reprint Stem cell therapy (Aastrom Biosciences Inc)
    M A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    IDrugs 3:346-53. 2000
    ..It now remains to be shown in a direct comparison that this approach yields greater efficacy and a lower cost than transplantation with unmanipulated large volume marrow or peripheral blood stem cell products...
  4. pmc Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
    Xiu Rong Ren
    Department of Medicine, Duke University Medical Center, 595 LaSalle Street, Durham, NC 27710, USA
    Breast Cancer Res 14:R89. 2012
    ..Thus, abrogation of persistent HER2 expression at the plasma membrane to synergize with current approaches may represent a novel therapeutic strategy...
  5. pmc Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines
    Fatima Rangwala
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    BMC Cancer 12:402. 2012
    ..The aim was to compare the chemosensitization potential of arsenic trioxide (ATO) in combination with sorafenib or fluorouracil (5-FU), in both hepatic tumor cells and stromal cells...
  6. pmc Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Immunol Immunother 62:1293-301. 2013
    ....
  7. doi request reprint Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma
    Michael A Morse
    Duke University Medical Center, Durham, NC, USA
    Clin Colorectal Cancer 11:185-90. 2012
    ..Embolizing branches of the hepatic artery lengthens survival for patients with unresectable hepatocellular carcinoma (HCC), but the benefit of combining chemotherapy with the embolizing particles remains controversial...
  8. pmc Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
    Antoni Ribas
    University of California, 11 934 Factor Building, UCLA Medical Center, Los Angeles, CA 90095 1782, USA
    J Transl Med 7:68. 2009
    ..18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune activation at the tumor site and in peripheral blood...
  9. pmc Investigation of HIFU-induced anti-tumor immunity in a murine tumor model
    Zhenlin Hu
    Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
    J Transl Med 5:34. 2007
    ..This response may play a critical role in a HIFU-elicited anti-tumor immune response which can be harnessed for more effective treatment...
  10. pmc Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
    Holden T Maecker
    BD Biosciences, San Jose, CA, USA
    BMC Immunol 9:9. 2008
    ..Here we assess the levels of intra-assay, inter-assay, and inter-operator precision, as well as linearity, of CD8+ T cell IFNgamma-based ELISPOT and cytokine flow cytometry (CFC), as well as tetramer assays...
  11. pmc Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:17. 2005
    ..In this study, we compared the performance of these assays on leukapheresed PBMC shipped overnight in medium versus cryopreserved PBMC from matched donors...
  12. ncbi request reprint Immunotherapy of cancer using dendritic cells
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cytokines Cell Mol Ther 4:35-44. 1998
    ..Phase I clinical trials have been initiated to address the safety and feasibility of immunizations with dendritic cells in humans with various malignancies...
  13. ncbi request reprint Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg Oncol 6:218-23. 1999
    ..This review will describe the background, rationale, and experimental approach of these clinical trials. Although equally promising, antibodies, gene therapies, and antiangiogenic strategies will not be discussed...
  14. ncbi request reprint A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 5:1331-8. 1999
    ..We conclude that it is feasible and safe to generate and administer large numbers of previously cryopreserved DCs loaded with CAP-1 peptide to patients with advanced malignancies...
  15. ncbi request reprint Technology evaluation: gene therapy (IL-2), Valentis Inc
    M A Morse
    Department of Medicine, Molecular Therapeutics Program, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 2:448-52. 2000
    ..Other routes of administration (intravenous and intratracheal), cytokines (IL-2) and proprietary liposomal-DNA complexes are being evaluated in preclinical models...
  16. ncbi request reprint Technology evaluation: CEA-TRICOM, Therion Biologics Corp
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 3:407-12. 2001
    ..The primary measure of immune response will be the level of CEA-specific T-cells stimulated by vaccination, with levels of CEA-expressing tumor cells in the blood used as a potential secondary measure of treatment effect [399610]...
  17. ncbi request reprint Dendritic cell maturation in active immunotherapy strategies
    Michael A Morse
    Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:35-43. 2002
    ....
  18. ncbi request reprint HER2 dendritic cell vaccines
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Breast Cancer 3:S164-72. 2003
    ..The magnitude of the immune responses generated is fairly modest, and more potent DC loading and maturation strategies will be necessary to optimize these vaccines...
  19. ncbi request reprint CEA loaded dendritic cell vaccines
    Michael A Morse
    Departments of Medicine and Surgery, Duke University Medical Center, P O Box 3233, Durham, NC 27710, USA
    Cancer Chemother Biol Response Modif 20:385-90. 2002
  20. ncbi request reprint Preparation of peptide-loaded dendritic cells for cancer immunotherapy
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Mol Biotechnol 25:95-9. 2003
    ..We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy...
  21. pmc Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
    ..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
  22. pmc Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
    Michael A Morse
    Department ofMedicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 112:610-8. 2008
    ....
  23. ncbi request reprint Technology evaluation: Stem-cell therapy, Aastrom Biosciences Inc
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 1:745-52. 1999
    ..It now remains to be shown in a direct comparison that this approach yields greater efficacy and a lower cost than transplantation with unmanipulated large volume marrow or peripheral blood stem cell products...
  24. ncbi request reprint A year of successful cancer vaccines points to a path forward
    Michael A Morse
    Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 12:11-3. 2010
    ..These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer...
  25. pmc An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 120:3234-41. 2010
    ..These data suggest that VRP-based vectors can overcome the presence of neutralizing antibodies to break tolerance to self antigen and may be clinically useful for immunotherapy in the setting of tumor-induced immunosuppression...
  26. pmc Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 17:4844-53. 2011
    ..We wished to test whether targeted delivery of an otherwise poorly immunogenic, soluble antigen to APC through their mannose receptors (MR) would induce clinically relevant immunity...
  27. doi request reprint CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer
    Michael A Morse
    Duke University Medical Center, 10 Bryan Searle Drive, 477 Seeley G Mudd Building, Durham, NC 27710, USA
    Expert Rev Vaccines 10:733-42. 2011
    ..An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-β-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit...
  28. ncbi request reprint The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..Autologous dendritic cells (DCs) loaded with tumor antigens are particularly potent at inducing tumor antigen-specific immune responses...
  29. ncbi request reprint Monitoring cellular immune responses to cancer immunotherapy
    M A Morse
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Curr Opin Mol Ther 3:45-52. 2001
    ..In this review, we will discuss these cellular immunological assays and the current status of their role in clinical trials of immunotherapy...
  30. ncbi request reprint Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 206:96-106. 2008
    ..The objective of this retrospective study was to determine if addition of bevacizumab to iri/oxal preoperative chemotherapy increases morbidity after hepatic resection...
  31. pmc Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
    T Osada
    Department of Surgery, Duke University Medical Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Br J Cancer 102:124-33. 2010
    ....
  32. ncbi request reprint A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment
    P J Mosca
    Departments of General and Thoracic Surgery, Pathology, Immunology, and Internal Medicine, Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, NC, USA
    Blood 96:3499-504. 2000
    ..These findings have important implications regarding the identification, characterization, and clinical application of functionally mature DCs...
  33. ncbi request reprint Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas
    R R White
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg Oncol 8:758-65. 2001
    ..Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT...
  34. pmc Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity
    T Osada
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Gene Ther 16:673-82. 2009
    ..These pre-clinical studies with E1 and E2b-deleted recombinant Ad5 vectors suggest that anti-Ad immunity will no longer be a limiting factor, and that clinical trials to evaluate their performance are warranted...
  35. ncbi request reprint A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon
    Brian G Czito
    Department ofRadiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 58:779-85. 2004
    ..We addressed the safety of oral eniluracil and 5-FU combined with preoperative radiotherapy and determined the recommended Phase II dose and dose-limiting toxicity in patients with locally advanced rectal and colon cancer...
  36. pmc Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
    Michael A Morse
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 126:2893-903. 2010
    ..Based on these results, we feel clinical studies using this approach to target HER2-overexpressing breast cancer, including trastuzumab- and lapatinib-resistant tumors is warranted...
  37. ncbi request reprint Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer
    M A Morse
    Departments of Medicine, Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 18:3883-93. 2000
    ..To evaluate preoperative dendritic cell (DC) mobilization and tumor infiltration after administration of Flt3 ligand (Flt3L) to patients with metastatic colon cancer...
  38. ncbi request reprint Clinical applications of dendritic cell vaccines
    M A Morse
    Departments of Medicine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 2:20-8. 2000
    ....
  39. ncbi request reprint Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer
    Rebekah R White
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, North Carolina 27710, USA
    Ann Surg Oncol 12:214-21. 2005
    ..We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection...
  40. ncbi request reprint Direct detection of cellular immune responses to cancer vaccines
    P J Mosca
    Department of Surgery, the Center for Genetic and Cellular Therapeutics, Duke University Medical Center, Durham, NC 27710, USA
    Surgery 129:248-54. 2001
    ....
  41. ncbi request reprint Assays for monitoring cellular immune responses to active immunotherapy of cancer
    T M Clay
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 7:1127-35. 2001
    ..We provide examples of how each has been used to monitor recent clinical trials and a discussion of how well each correlates with clinical outcome...
  42. ncbi request reprint Immunotherapy of surgical malignancies
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina, USA
    Curr Probl Surg 41:15-132. 2004
  43. ncbi request reprint Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis
    Amy C Hobeika
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunother 28:63-72. 2005
    ..These assays will better define the quantity and quality of protective immune responses to viral disease and offer insight into the requirements for protective anti-cancer immunity...
  44. ncbi request reprint Depletion of human regulatory T cells (Treg) and antigen-specific immune responses to cancer vaccines
    T M Clay
    Duke University Medical Center, Durham, NC
    J Clin Oncol 26:3010. 2008
    ..Conversely, depletion of Treg leads to immune enhancement. The immunotoxin denileukin diftitox which selectively targets lymphocytes expressing CD25 may deplete FoxP3+ Treg...
  45. pmc Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy
    M A Morse
    Division of Hematology Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg 226:6-16. 1997
    ....
  46. ncbi request reprint Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
    ....
  47. ncbi request reprint Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand
    Paul J Mosca
    Department of General and Thoracic Surgery, Pathology, Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Leukoc Biol 72:546-53. 2002
    ..The ability to generate phenotypically mature, IL-12-producing DC1 from peripheral blood mononuclear cells mobilized by Flt3L will have important implications for the development of effective cancer immunotherapy strategies...
  48. ncbi request reprint Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs
    Takuya Osada
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Int Immunol 17:1143-55. 2005
    ..Conversely, the use of NKT cells along with anti-Th2 cytokine-neutralizing antibodies or CD4-negative NKT cell subset could enhance the generation of antigen-specific CTLs for adoptive immunotherapy...
  49. ncbi request reprint NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity
    Takuya Osada
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Cancer Immunol Immunother 55:1122-31. 2006
    ..14). Thus, NK responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses. Monitoring of NK response during vaccine studies should be routinely performed...
  50. pmc Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors
    Elizabeth Dugan
    Duke University Medical Center, Durham, NC, 27710, USA
    Anticancer Res 29:5149-53. 2009
    ..To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination...
  51. pmc An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity
    Zachary C Hartman
    Department of Surgery, Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 16:1466-77. 2010
    ..We designed and tested several HER2 vaccines devoid of oncogenic activity to develop a safe vaccine for clinical use...
  52. ncbi request reprint Quantitating therapeutically relevant T-cell responses to cancer vaccines
    A C Hobeika
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Crit Rev Immunol 21:287-97. 2001
    ..We also propose a strategy for efficiently evaluating the immunologic efficacy of cancer vaccines so that the most promising candidates can be brought more rapidly into definitive clinical trials...
  53. ncbi request reprint DNA and RNA modified dendritic cell vaccines
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, North Carolina 27710, USA
    World J Surg 26:819-25. 2002
    ..Genetic modification can be effected by either DNA or RNA, and the genetic material may be delivered by vectors or by physical means. These approaches are now entering human clinical trials...
  54. ncbi request reprint Combining cancer vaccines with chemotherapy
    Gabriel Chong
    Division of Medical Oncology, Duke South Clinics, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Pharmacother 6:2813-20. 2005
    ..As such, more preclinical and clinical trials are needed to explore the synergistic effects of chemotherapy combined with immunotherapy, particularly the proper dose and timing of chemotherapy...
  55. ncbi request reprint Dendritic cell-based immunotherapy
    Takuya Osada
    Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int Rev Immunol 25:377-413. 2006
    ..In addition, issues regarding the optimal dose and clinical setting for the application of DC vaccines remain to be resolved, and recent clinical studies have been designed to begin to address these questions...
  56. doi request reprint Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function
    M A Morse
    Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Gene Ther 19:30-7. 2012
    ..In summary, modulation of T(reg) levels using the FOXP3 PPMO antisense-based genomic strategy has the potential to optimize immunotherapy strategies in cancer and viral immunotherapy...
  57. ncbi request reprint Technology evaluation: BLP-25, Biomira Inc
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 3:102-5. 2001
    ....
  58. ncbi request reprint Technology evaluation: Theratope, Biomira Inc
    M A Morse
    Duke University Medical Center, Department of Surgery, Immunology and Pathology, Durham, NC 27710, USA
    Curr Opin Mol Ther 2:453-8. 2000
    ..Other malignancies for which the vaccine may be applicable include ovarian and gastrointestinal cancers...
  59. ncbi request reprint Current status of adoptive immunotherapy of malignancies
    Michael A Morse
    Department of Medicine and Surgery, Duke University Medical Center, MSRB Room 401, Box 3233, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:237-47. 2002
    ..In addition to work being done to develop the most potent effector, other studies are working on improving T-cell trafficking to tumours and interfering with the tumour-induced immunosuppression that can impair in vivo T-cell activity...
  60. ncbi request reprint Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis
    Pierre Alain Clavien
    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Gastrointest Surg 6:95-101. 2002
    ..TACE may reduce the risk of hemorrhage after cryosurgery but can increase the risk of hepatic failure in patients with poor hepatic function...
  61. ncbi request reprint Immunoregulatory T cells in cancer immunotherapy
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:827-34. 2002
    ..One hypothesis is that depleting these CD4+CD25+ counter-regulatory T cells in humans with cancer will enhance the efficacy of anticancer immunisations...
  62. ncbi request reprint Proteomics for monitoring immune responses to cancer vaccines
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
    Curr Opin Mol Ther 5:39-43. 2003
    ..Advances in miniaturization and automation may also permit characterization of the immune response more rapidly and from smaller amounts of biological material than is possible with existing assay systems...
  63. ncbi request reprint Current status of dendritic cell immunotherapy of malignancies
    Paul J Mosca
    Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Int Rev Immunol 22:255-81. 2003
    ..Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer...
  64. ncbi request reprint Toward protecting the safety of participants in clinical trials
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Control Clin Trials 24:256-71. 2003
    ..DMC composition and functions should be standardized and regulations should be harmonized nationally and internationally. Finally, there should be a concerted effort to study the efficacy of various components of the system...
  65. ncbi request reprint Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
    ..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
  66. ncbi request reprint Recent areas of development for dendritic cell vaccines
    Michael A Morse
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Biol Response Modif 21:339-50. 2003
  67. ncbi request reprint Successful desensitization to oxaliplatin
    Lydia Mis
    Department of Pharmacy, Duke University Medical Center, Durham, NC 27710 3089, USA
    Ann Pharmacother 39:966-9. 2005
    ..To report the successful desensitization of a patient to oxaliplatin utilizing an 8-hour desensitization regimen in a controlled environment...
  68. ncbi request reprint Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:3017-24. 2005
    ..To determine the safety and immunologic and clinical efficacy of a dendritic cell vaccine modified to hyperexpress costimulatory molecules and tumor antigen...
  69. ncbi request reprint Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 62:1030-4. 2005
    ..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken...
  70. ncbi request reprint Virus-based therapies for colon cancer
    Michael A Morse
    Division of Medical Oncology, Duke University Medical Center, Duke South Clinics, Durham, NC 27710, USA
    Expert Opin Biol Ther 5:1627-33. 2005
    ..As considerable research has focused on therapy of colon cancer with viral vectors, this review will illustrate the major concepts of viral therapy of cancers with examples from studies targeting colorectal carcinoma...
  71. ncbi request reprint Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer
    Michael A Morse
    Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
    IDrugs 8:974-7. 2005
  72. ncbi request reprint Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb
    Michael A Morse
    Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA
    Curr Opin Mol Ther 7:588-97. 2005
    ....
  73. ncbi request reprint Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:656-62. 2006
    ..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer...
  74. ncbi request reprint Role of natural killer cell function in dendritic cell-based vaccines
    Christopher Y Woo
    Program in Molecular Therapeutics, Comprehensive Cancer Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Vaccines 5:55-65. 2006
    ..In this article, the authors will review studies focusing on NK-DC interactions and highlight the most recent clinical findings relating to the potential role of NK cells in DC-based vaccine therapy...
  75. ncbi request reprint A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Invest 24:9-17. 2006
    ..We addressed the safety of oral eniluracil/5-FU combined with radiation therapy and determined the profile of dose-limiting toxicities and recommended Phase II dose (RPTD) in patients with pancreatic and hepatobiliary cancers...
  76. ncbi request reprint Gene therapy for lung cancer
    Eric M Toloza
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Cell Biochem 99:1-22. 2006
    ..This article will discuss the therapeutic implications of these molecular changes associated with bronchogenic carcinomas and will then review the status of gene therapies for treatment of lung cancer...
  77. ncbi request reprint Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review
    Robert G Prosnitz
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 107:2352-60. 2006
    ..Therefore, the authors conducted a systematic review of the literature to determine the available QMs for adjuvant CT and RT in patients with CRC and rated their usefulness for assessing the delivery of quality care...
  78. ncbi request reprint Recent clinical progress in virus-based therapies for cancer
    Christopher Y Woo
    Duke University Medical Center, Department of Medicine, Programme in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Expert Opin Biol Ther 6:1123-34. 2006
    ..This review highlights the principles underlying virus-based therapies for cancer, with an emphasis on recent developments from the clinic...
  79. ncbi request reprint A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 67:1002-7. 2007
    ..The optimal combination of chemotherapeutic agents with RT is undefined. We evaluated a combination of capecitabine, carboplatin, and paclitaxel with RT in a phase I study...
  80. ncbi request reprint Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27713, USA
    J Am Coll Surg 204:372-82. 2007
    ..Although established for metastatic colorectal (CR) and neuroendocrine (NE) malignancies, the role of partial hepatectomy in management of metastases from other primaries (NCRNE) is not well-defined...
  81. ncbi request reprint Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
    Benjamin F Johnson
    Duke University Medical Center, Duke University School of Medicine, Department of Medicine, Program in Molecular Therapeutics, Comprehensive Cancer Center, Box 2606, Durham, NC 27710, USA
    Expert Opin Biol Ther 7:449-60. 2007
    ..Several strategies tested so far have yielded incomplete, yet promising, results...
  82. ncbi request reprint Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 68:472-8. 2007
    ..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer...
  83. ncbi request reprint Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy
    Chris R Kelsey
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:1436-41. 2007
    ..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)...
  84. ncbi request reprint CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy
    Yanal M Murad
    Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 7:1257-66. 2007
    ..Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer...
  85. ncbi request reprint Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 14:3481-91. 2007
    ..This multi-institutional retrospective study compared postoperative outcomes after simultaneous and staged colorectal and hepatic resections...
  86. ncbi request reprint Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:770-6. 2007
    ..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer...
  87. ncbi request reprint Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature)
    Meenal Patwardhan
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Eval Clin Pract 13:831-45. 2007
    ..We also evaluated the extent to which these measures are ready to be implemented in clinical practice, and identified areas for future research...
  88. pmc The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
    Takuya Osada
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Cancer Immunol Immunother 57:1115-24. 2008
    ..These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies...
  89. doi request reprint Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA
    J Gastrointest Surg 13:74-84. 2009
    ..The objective of this retrospective study was to determine the effect of multiagent chemotherapy on long-term survival after resection of CLM...
  90. pmc Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
    John W Nelson
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 73:148-53. 2009
    ..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy...
  91. doi request reprint Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 16:1809-19. 2009
    ..However, prospective randomized trials are needed to determine the optimal timing of chemotherapy...
  92. ncbi request reprint Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
    Michael A Morse
    Duke University Medical Center, Durham, NC, USA
    Expert Opin Biol Ther 9:331-9. 2009
    ..Vaccines for pancreatic cancer have been challenged by a number of factors, especially the immunosuppressive microenvironment within the tumor that allows for escape from immune surveillance...
  93. pmc Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine
    Takuya Osada
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 15:2789-96. 2009
    ....
  94. ncbi request reprint Treatment-related toxicity and supportive care in metastatic colorectal cancer
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, 2424 Erwin Road, Suite G05, Hock Plaza, DUMC Box 2732, Durham, NC 27710, USA
    J Support Oncol 8:15-20. 2010
    ..These data, obtained from a usual-practice setting, provide benchmarks to improve clinical practice...
  95. doi request reprint Adenovirus vaccine immunotherapy targeting WT1-expressing tumors
    Jeffrey M Clarke
    Department of Medicine, Duke University Medical Center, DUMC Box 31379, Durham, NC 27710, USA
    Expert Opin Biol Ther 10:875-83. 2010
    ..Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy...
  96. ncbi request reprint Pharmacological inhibition of TGFβ as a strategy to augment the antitumor immune response
    Brent A Hanks
    Department of Internal Medicine, Division of Hematology and Oncology, Duke University Medical Center, 450 Research Drive, Durham, NC 27708, USA
    Curr Opin Investig Drugs 11:1342-53. 2010
    ....
  97. doi request reprint Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer
    C Aggarwal
    Department of Medicine, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 24:420-8. 2013
    ..This secondary analysis assessed the relationship of the CTC number with carcinoembryonic antigen (CEA) and overall survival...
  98. ncbi request reprint Technology evaluation: VEGF165 gene therapy, Valentis Inc
    M A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 3:97-101. 2001
    ..Valentis also intended to evaluate the gene therapy system in a rabbit ischemia model and complete the necessary preclinical studies for submission of an IND [318137]...
  99. pmc ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers
    G Sinnathamby
    Immunotope, Inc, The Pennsylvania Biotechnology Center, Doylestown, PA 18902, USA
    Clin Exp Immunol 163:324-32. 2011
    ..Collectively, our data present evidence that ADAM17 can be a potential target antigen to devise novel immunotherapeutic strategies against ovarian, breast and prostate cancer...
  100. pmc X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity
    M K Evans
    Division of Surgical Sciences, Department of Surgery, Duke University Medical Center, Durham, NC, USA
    Cell Death Dis 7:e2073. 2016
    ..These results suggest that strategies targeting the effects of XIAP on caspase activation and ROS suppression have the potential to enhance the activity of monoclonal antibody-based immunotherapy. ..
  101. ncbi request reprint E/Tablets to collect research-quality, patient-reported data
    H E Uronis
    Duke University, Durham, NC
    J Clin Oncol 26:17528. 2008
    ..Can e/Tablets deployed in outpatient oncology clinics be used to collect research survey data that are comparable to paper-based data?..

Research Grants2

  1. DEXASOME BASED IMMUNOTHERAPY OF LUNG CANCER
    Michael Morse; Fiscal Year: 2002
    ..This clinical trial will form the background for further trials designed to demonstrate both immunology and clinical benefits of dexosome-based immunotherapy. ..
  2. Vaccination with Regulatory T Cell Depletion
    Michael Morse; Fiscal Year: 2007
    ..Future studies will assess whether the greater magnitude and durability of the CEA-specific immune responses will translate into a long-term clinical benefit. [unreadable] [unreadable] [unreadable]..